Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Accumulated Expenses data on record, last reported at $65869.0 in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 80.47% year-over-year to $65869.0; the TTM value through Dec 2025 reached $65869.0, down 80.47%, while the annual FY2025 figure was $73143.0, 85.02% down from the prior year.
  • Accumulated Expenses reached $65869.0 in Q4 2025 per INM's latest filing, down from $111662.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $488278.0 in Q2 2024 and bottomed at $54629.0 in Q1 2024.
  • Average Accumulated Expenses over 5 years is $223594.9, with a median of $139120.0 recorded in 2022.
  • The widest YoY moves for Accumulated Expenses: up 750.58% in 2025, down 85.02% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $382114.0 in 2021, then plummeted by 63.59% to $139120.0 in 2022, then fell by 26.84% to $101775.0 in 2023, then skyrocketed by 231.35% to $337236.0 in 2024, then crashed by 80.47% to $65869.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $65869.0 in Q4 2025, $111662.0 in Q3 2025, and $73143.0 in Q2 2025.